Comparative Pharmacology
Head-to-head clinical analysis: H R 50 versus TESTOSTERONE PROPIONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: H R 50 versus TESTOSTERONE PROPIONATE.
H.R.-50 vs TESTOSTERONE PROPIONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective estrogen receptor degrader (SERD); binds to estrogen receptor alpha, inducing degradation and inhibiting estrogen signaling.
Testosterone propionate is a short-acting androgen receptor agonist. It binds to androgen receptors, leading to activation of androgen-responsive genes and promotion of male secondary sexual characteristics, anabolic effects, and erythropoiesis.
12.5 mg orally twice daily
50-400 mg intramuscularly every 2-4 weeks. For androgen replacement, 50-100 mg IM every 2 weeks.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 10-12 hours in moderate renal impairment (CrCl <50 mL/min).
Clinical Note
moderateTestosterone propionate + Tranylcypromine
"The risk or severity of adverse effects can be increased when Testosterone propionate is combined with Tranylcypromine."
Clinical Note
moderateTestosterone propionate + Procarbazine
"The risk or severity of adverse effects can be increased when Testosterone propionate is combined with Procarbazine."
Clinical Note
moderateTestosterone propionate + Pirlindole
"The risk or severity of adverse effects can be increased when Testosterone propionate is combined with Pirlindole."
Clinical Note
moderateTerminal half-life: 0.8–1.2 hours (rapid elimination due to short ester chain; requires frequent dosing).
Renal excretion of unchanged drug accounts for 60-70%; biliary/fecal excretion accounts for 20-30%; <10% metabolized.
Renal: 90% (as glucuronide and sulfate conjugates); Fecal/Biliary: 10%.
Category C
Category D/X
Androgen
Androgen
Testosterone propionate + Moclobemide
"The risk or severity of adverse effects can be increased when Testosterone propionate is combined with Moclobemide."